Noninvasive Evaluation of Tumoral PD-L1 Using a Novel <sup>99m</sup>Tc-Labeled Nanobody Tracer with Rapid Renal Clearance-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Noninvasive Evaluation of Tumoral PD-L1 Using a Novel ^99mTc-Labeled Nanobody Tracer with Rapid Renal Clearance

Published:2024-02-23 Issue:4 Volume:21 Page:1977-1986
ISSN:1543-8384
Container-title:Molecular Pharmaceutics
language:en
Short-container-title:Mol. Pharmaceutics

Author:

Hu Biao¹²,Ma Xiaopan³,Shi Linqing¹,Liu Tianyu¹,Li Liqiang¹,Yao Meinan¹,Li Chenzhen¹,Jia Bing¹⁴^ORCID

Affiliation:

1. Department of Radiation Medicine, School of Basic Medical Sciences, Peking University, Beijing 100191, China

2. Department of Nuclear Medicine, Molecular Imaging Lab, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China

3. Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing 100142, China

4. Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Beijing 100191, China

Funder

National Natural Science Foundation of China

Science and Technology Development Fund of Beijing Anzhen Hospital

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.molpharmaceut.3c01219

Reference34 articles.

1. Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

2. T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028

3. Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

4. Association of PD‐L1 expression status with the efficacy of PD‐1/PD‐L1 inhibitors and overall survival in solid tumours: A systematic review and meta‐analysis

5. Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3